Olivia Kincaid, in Pearl, MS - Occupational Therapist

Olivia Kincaid, is a Occupational Therapist based in Pearl, Mississippi. Olivia Kincaid is licensed to practice in Mississippi (license number ) and her current practice location is 5420 Highway 80 E, Pearl, Mississippi. She can be reached at her office (for appointments etc.) via phone at (601) 988-6800.

NPI number for Olivia Kincaid is 1588356703 and her current mailing address is 761 Rice Rd Apt 1006, Ridgeland, Mississippi. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1588356703.

Contact Information

	Olivia Kincaid,
	5420 Highway 80 E, Pearl, MS 39208-8924
	(601) 988-6800
	Not Available

Healthcare Provider's Profile

Full Name	Olivia Kincaid
Gender	Female
Speciality	Occupational Therapist
Location	5420 Highway 80 E, Pearl, Mississippi
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1588356703
Provider Enumeration Date: 05/25/2023
Last Update Date: 05/31/2023

Medical Identifiers

Medical identifiers for Olivia Kincaid such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1588356703	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225X00000X	Occupational Therapist	(Mississippi)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Olivia Kincaid is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Olivia Kincaid, 761 Rice Rd Apt 1006, Ridgeland, MS 39157-1093 Ph: (502) 552-2906	Olivia Kincaid, 5420 Highway 80 E, Pearl, MS 39208-8924 Ph: (601) 988-6800

News Archive

FDA and EC grant Orphan Drug Designation to Boehringer's volasertib for acute myeloid leukemia

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML).

New p53 knockout rat model improves timelines for carcinogenicity screening

Sigma Life Science, the innovative biological products and services brand of Sigma-Aldrich, today introduced the world's first p53 'knockout' rat model, an important development that is expected to, due to the rat's closer physiological and metabolic similarity to humans, significantly improve timelines for carcinogenicity screening and reduce time to market for therapeutics.

Obama gives Latinos full court press

The president appeared at a town-hall-style event Thursday, hosted by Spanish-language media outlets, to urge Latinos to sign up for insurance options made available by the health law before open enrollment ends March 31.

PAN-EX supports neoadjuvant chemotherapy in high-risk rectal cancer

Patients with high-risk, locally advanced rectal cancer could benefit from neoadjuvant chemotherapy before undergoing chemoradiotherapy, suggest the results of a pooled analysis.

Olivia Kincaid, - Occupational Therapist in Pearl, MS